NELFE promoted pancreatic cancer metastasis and the epithelial‑to‑mesenchymal transition by decreasing the stabilization of NDRG2 mRNA

Han,Lili; Zan,Ying; Huang,Chen; Zhang,Shuqun

doi:10.3892/ijo.2019.4890

NELFE promoted pancreatic cancer metastasis and the epithelial‑to‑mesenchymal transition by decreasing the stabilization of NDRG2 mRNA

Authors:
- Lili Han
- Ying Zan
- Chen Huang
- Shuqun Zhang
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: October 2, 2019 https://doi.org/10.3892/ijo.2019.4890
Pages: 1313-1323
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Negative elongation factor E (NELFE) has been demonstrated to promote cancer progression as an RNA‑binding protein (RBP). However, the expression patterns, biological role and molecular mechanism of NELFE in pancreatic cancer (PC) remain largely unknown. The expression levels of NELFE in 120 pairs of PC tissues and adjacent non‑tumor clinical samples collected from patients with PC were examined via reverse transcription‑quantitative (RT‑q) PCR and immunohistochemistry. The mRNA expression levels of NELFE, N‑Myc downstream‑regulated gene 2 (NDRG2), c‑Myc, survivin and cyclin D1 were detected via RT‑qPCR. The protein expression levels of NELFE, NDRG2, total β‑catenin, nuclear β‑catenin, cytosolic β‑catenin, E‑cadherin, N‑cadherin and Vimentin were measured by western blotting. NELFE and NDRG2 were then knocked‑down by short hairpin (sh)RNA. PC cell proliferation was detected by MTT and colony formation assays. Invasion and migration were detected by transwell assays. The interaction between NELFE and NDRG2 was detected by luciferase reporter assays, mRNA decay assays and RNA immunoprecipitation. NELFE expression was increased in PC tissues compared with the paired non‑cancerous tissues. NELFE expression was upregulated in PC cells when compared with normal pancreatic cells (HPDE6‑C7). The present study revealed that knockdown of NELFE inhibited the proliferation, invasion and migration of PC cells. In addition, transfection of the sh‑NELFE vector inhibited the epithelial‑to‑mesenchymal transition in PC cells by suppressing the expression and nuclear accumulation of β‑catenin. Further mechanistic studies revealed that NELFE activates the Wnt/β‑catenin signaling pathway by decreasing the stabilization of NDRG2 mRNA in PC. To the best of our knowledge, these results revealed the promotional function of NELFE on PC tumorigenesis and metastasis for the first time, helping to provide a promising strategy for the treatment of patients with PC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Wang L, Yang GH, Li H and Lu XH: The changing pancreatic cancer mortality in China (1991-2000). Zhonghua Nei Ke Za Zhi. 44:509–513. 2005.In Chinese. PubMed/NCBI
3	Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, Gloor B and Koeberle D: Modest improvement in overall survival for patients with metastatic pancreatic cancer: A trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 42:1157–1163. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
5	Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
6	Gonzalez DM and Medici D: Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 7:re82014. View Article : Google Scholar : PubMed/NCBI
7	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
8	Scaturrok M, Sala A, Cutrona G, Raimondi L, Cannino G, Fontana S, Pucci-Minafra I and Di Liegro I: Purification by affinity chromatography of H1o RNA-binding proteins from rat brain. Int J Mol Med. 11:509–513. 2003.PubMed/NCBI
9	Roesch A, Becker B, Meyer S, Wild P, Hafner C, Landthaler M and Vogt T: Retinoblastoma-binding protein 2-homolog 1: A retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol. 18:1249–1257. 2005. View Article : Google Scholar : PubMed/NCBI
10	Hodson DJ, Screen M and Turner M: RNA binding proteins in hematopoiesis and hematological malignancy. Blood. 133:2365–2373. 2019. View Article : Google Scholar : PubMed/NCBI
11	Hentze MW, Castello A, Schwarzl T and Preiss T: A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 19:327–341. 2018. View Article : Google Scholar : PubMed/NCBI
12	Narita T, Yung TM, Yamamoto J, Tsuboi Y, Tanabe H, Tanaka K, Yamaguchi Y and Handa H: NELF interacts with CBC and participates in 3′ end processing of replication-dependent histone rnRNAs. Mol Cell. 26:349–365. 2007. View Article : Google Scholar : PubMed/NCBI
13	Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, Hughes TR and Wang XW: Oncogenic activation of the RNA binding protein NELFE and MYC signaling in hepatocellular carcinoma. Cancer Cell. 32:101–114.e8. 2017. View Article : Google Scholar : PubMed/NCBI
14	Han LL, Nan HC, Tian T, Guo H, Hu TH, Wang WJ, Ma JQ, Jiang LL, Guo QQ, Yang CC, et al: Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma. Oncol Rep. 31:2569–2578. 2014. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Liu L, Xu HX, He M, Wang W, Wang WQ, Wu CT, Wei RQ, Liang Y, Gao HL, Liu C, et al: A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. Surgery. 163:1280–1294. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhou P, Li Y, Li B, Zhang M, Liu Y, Yao Y and Li D: NMIIA promotes tumor growth and metastasis by activating the Wnt/β-catenin signaling pathway and EMT in pancreatic cancer. Oncogene. 38:5500–5515. 2019. View Article : Google Scholar : PubMed/NCBI
18	Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, Zhao Y, Harris DC and Zheng G: Ecadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011:5673052011. View Article : Google Scholar
19	Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, et al: Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer. 7:1922007. View Article : Google Scholar : PubMed/NCBI
20	Kang K, Nam S, Kim B, Lim JH, Yang Y, Lee MS and Lim JS: Inhibition of osteoclast differentiation by overexpression of NDRG2 in monocytes. Biochem Biophys Res Commun. 468:611–616. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Li F, Liu X, Shen L, Liu J, Su J, Zhang W, Deng Y, Wang L, Liu N, et al: The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J Biol Chem. 281:39159–39168. 2006. View Article : Google Scholar : PubMed/NCBI
22	Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X and Yao LB: NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol. 10:3518–3521. 2004. View Article : Google Scholar : PubMed/NCBI
23	Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J and Handa H: NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell. 97:41–51. 1999. View Article : Google Scholar : PubMed/NCBI
24	Vos SM, Pöllmann D, Caizzi L, Hofmann KB, Rombaut P, Zimniak T, Herzog F and Cramer P: Architecture and RNA binding of the human negative elongation factor. Elife. 5:e149812016. View Article : Google Scholar : PubMed/NCBI
25	Price DH: Regulation of RNA polymerase II elongation by c-Myc. Cell. 141:399–400. 2010. View Article : Google Scholar : PubMed/NCBI
26	Midorikawa Y, Tsutsumi S, Taniguchi H, Ishii M, Kobune Y, Kodama T, Makuuchi M and Aburatani H: Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res. 93:636–643. 2002. View Article : Google Scholar : PubMed/NCBI
27	McChesney PA, Aiyar SE, Lee OJ, Zaika A, Moskaluk C, Li R and El-Rifai W: Cofactor of BRCA1: A novel transcription factor regulator in upper gastrointestinal adenocarcinomas. Cancer Res. 66:1346–1353. 2006. View Article : Google Scholar : PubMed/NCBI
28	Wu CH, Lee C, Fan R, Smith MJ, Yamaguchi Y, Handa H and Gilmour DS: Molecular characterization of Drosophila NELF. Nucleic Acids Res. 33:1269–1279. 2005. View Article : Google Scholar : PubMed/NCBI
29	Sun J, Watkins G, Blair AL, Moskaluk C, Ghosh S, Jiang WG and Li R: Deregulation of cofactor of BRCA1 expression in breast cancer cells. J Cell Biochem. 103:1798–1807. 2008. View Article : Google Scholar
30	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
31	Cui W, Meng W, Zhao L, Cao H, Chi W and Wang B: TGF-β-induced long non-coding RNA MIR155HG promotes the progression and EMT of laryngeal squamous cell carcinoma by regulating the miR-155-5p/SOX10 axis. Int J Oncol. 54:2005–2018. 2019.PubMed/NCBI
32	Nie J, Jiang HC, Zhou YC, Jiang B, He WJ, Wang YF and Dong J: MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT. Biosci Biotechnol Biochem. 83:1062–1071. 2019. View Article : Google Scholar : PubMed/NCBI
33	Zhang HG, Pan YW, Feng J, Zeng CT, Zhao XQ, Liang B and Zhang WW: TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway. Eur Rev Med Pharmacol Sci. 23:2003–2012. 2019.PubMed/NCBI
34	Nam Y, Weng AP, Aster JC and Blacklow SC: Structural requirements for assembly of the CSL.intracellular Notch1. Mastermind-like 1 transcriptional activation complex. J Biol Chem. 278:21232–21239. 2003. View Article : Google Scholar : PubMed/NCBI
35	Peng G and Liu Y: Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol Sci. 36:374–383. 2015. View Article : Google Scholar : PubMed/NCBI
36	Oh SJ, Shin JH, Kim TH, Lee HS, Yoo JY, Ahn JY, Broaddus RR, Taketo MM, Lydon JP, Leach RE, et al: β-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition. J Pathol. 231:210–222. 2013. View Article : Google Scholar : PubMed/NCBI
37	Kechavarzi B and Janga SC: Dissecting the expression landscape of RNA-binding proteins in human cancers. Genome Biol. 15:R142014. View Article : Google Scholar : PubMed/NCBI
38	Gerstberger S, Hafner M and Tuschl T: A census of human RNA-binding proteins. Nat Rev Genet. 15:829–845. 2014. View Article : Google Scholar : PubMed/NCBI
39	Galante PA, Sandhu D, de Sousa Abreu R, Gradassi M, Slager N, Vogel C, de Souza SJ and Penalva LO: A comprehensive in silico expression analysis of RNA binding proteins in normal and tumor tissue: Identification of potential players in tumor formation. RNA Biol. 6:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
40	Adelman K and Lis JT: Promoter-proximal pausing of RNA polymerase II: Emerging roles in metazoans. Nat Rev Genet. 13:720–731. 2012. View Article : Google Scholar : PubMed/NCBI
41	Li J, Liu Y, Rhee HS, Ghosh SK, Bai L, Pugh BF and Gilmour DS: Kinetic competition between elongation rate and binding of NELF controls promoter proximal pausing. Mol Cell. 50:711–722. 2013. View Article : Google Scholar : PubMed/NCBI
42	Pagano JM, Kwak H, Waters CT, Sprouse RO, White BS, Ozer A, Szeto K, Shalloway D, Craighead HG and Lis JT: Defining NELF-E RNA binding in HIV-1 and promoter-proximal pause regions. PLoS Genet. 10:e10040902014. View Article : Google Scholar : PubMed/NCBI
43	Dang H, Pomyen Y, Martin SP, Dominguez DA, Yim SY, Lee JS, Budhu A, Shah AP, Bodzin AS and Wang XW: NELFE-dependent MYC signature identifies a unique cancer subtype in hepatocellular carcinoma. Sci Rep. 9:33692019. View Article : Google Scholar : PubMed/NCBI
44	Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, et al: N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 106:342–347. 2003. View Article : Google Scholar : PubMed/NCBI
45	Chen XL, Lei L, Hong LL and Ling ZQ: Potential role of NDRG2 in reprogramming cancer metabolism and epithelial-to-mesenchymal transition. Histol Histopathol. 33:655–663. 2018.
46	Kim MJ, Lim J, Yang Y, Lee MS and Lim JS: N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling. Cancer Lett. 354:33–42. 2014. View Article : Google Scholar : PubMed/NCBI
47	Moradi Monfared M, Alizadeh Zarei M, Rafiei Dehbidi G, Behzad Behbahani A, Arabsolghar R and Takhshid MA: NDRG2 regulates the expression of genes involved in epithelial mesenchymal transition of prostate cancer cells. Iran J Med Sci. 44:118–126. 2019.PubMed/NCBI
48	Yang CL, Zheng XL, Ye K, Ge H, Sun YN, Lu YF and Fan QX: NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway. Int J Biochem Cell Biol. 99:43–51. 2018. View Article : Google Scholar : PubMed/NCBI
49	Kim YJ, Yoon SY, Kim JT, Song EY, Lee HG, Son HJ, Kim SY, Cho D, Choi I, Kim JH and Kim JW: NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis. 30:598–605. 2009. View Article : Google Scholar : PubMed/NCBI
50	Xu X, Li J, Sun X, Guo Y, Chu D, Wei L, Li X, Yang G, Liu X, Yao L, et al: Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression. Oncotarget. 6:26161–26176. 2015. View Article : Google Scholar : PubMed/NCBI